NCT05083949View on ClinicalTrials.gov

A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 23, 2021

Primary Completion Date

August 6, 2021

Study Completion Date

September 9, 2021

Conditions
Healthy
Interventions
DRUG

FDC 12.5mg empagliflozin/850mg metformin

empagliflozin/metformin

DRUG

Empagliflozin

empagliflozin 10mg (R1)

DRUG

Glifage®

Glifage® 850mg (R2)

Trial Locations (1)

74935-530

Instituto de Ciências Farmacêuticas de Estudos e Pesquisas - ICF, Goiânia

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05083949 - A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together | Biotech Hunter | Biotech Hunter